iShares Nasdaq Biotechnology Index Fund ETF News

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

On a relative basis, biotech and pharmaceutical indexes outperformed the S&P 500 by 18% and 10%, respectively, in the past three recessions, according to SVB Leerink analyst Geoffrey Porges.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs April 23.) Arcturus Therapeutics Ltd...

Centaurus Financial Inc. cut its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 54.4% in the first quarter, Holdings Channel.com reports. The institutional investor owned 1,643

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

University of Alabama at Birmingham School of Public Health Epidemiologist Suzanne Judd, Ph.D. joins Yahoo Finance’s Seana Smith to discuss the latest coronavirus developments, as a new CBS poll rev

Biotech stocks have been the poster child of relative strength in recent weeks. Relative strength (not to be confused with the Relative Strength Index) measures the performance of a stock or index aga

These two underrated biotech stocks have the potential to soar.

Biotech companies mostly list their stocks at the clinical trial stage, without even starting to make revenues.